PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.72%
EBIT growth 1.25-1.5x TRVN's 5.20%. Bruce Berkowitz would verify if strategic initiatives are driving this edge.
7.72%
Operating income growth 1.25-1.5x TRVN's 5.20%. Bruce Berkowitz would see if strategic measures (e.g., cost cutting, product mix) are succeeding.
12.50%
Net income growth above 1.5x TRVN's 1.36%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
15.94%
EPS growth above 1.5x TRVN's 3.85%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
15.94%
Diluted EPS growth above 1.5x TRVN's 3.85%. David Dodd would see if there's a robust moat protecting these shareholder gains.
4.10%
Share count expansion well above TRVN's 2.61%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
4.10%
Diluted share count expanding well above TRVN's 2.61%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-32.84%
Negative OCF growth while TRVN is at 37.88%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-32.79%
Negative FCF growth while TRVN is at 31.69%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-48098.63%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-29341.33%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-23.11%
Negative 3Y OCF/share CAGR while TRVN stands at 14.25%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-39968.68%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-32.05%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-188.96%
Negative 3Y CAGR while TRVN is 19.85%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
7755.72%
Positive growth while TRVN is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
2687.68%
Positive 5Y equity/share CAGR while TRVN is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
-9.18%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.88%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-33.82%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
-2.78%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-14.34%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.